Carmot Therapeutics, Inc.
Clinical trials sponsored by Carmot Therapeutics, Inc., explained in plain language.
-
New drug shows promise for diabetes and weight loss
Disease control CompletedThis study tested an investigational drug called CT-868 to see if it could help lower blood sugar and reduce body weight in adults with type 2 diabetes who are also overweight or obese. Over 100 participants received either the drug or a placebo for 26 weeks. The main goal was to…
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Weekly shot shows promise for significant weight loss in major trial
Disease control CompletedThis study tested a new weekly injection called CT-388 to see if it helps people with obesity or overweight lose weight and improve related health measures. Nearly 470 adults received either the drug or a placebo (dummy injection) for 48 weeks. The main goal was to measure the pe…
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New injection tested for weight loss and diabetes control
Disease control CompletedThis early-stage study tested the safety and effects of a new injectable drug called CT-388. It involved 129 overweight or obese adults, some with type 2 diabetes. Researchers measured how the body processes the drug and its impact on weight and blood sugar levels.
Phase: PHASE1 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC